Obesity and Diabetes Mellitus, Type 2NCT07922694
Obesity-Related Indices and Albuminuria in Type 2 Diabetes
An observational study of Obesity and Diabetes Mellitus, Type 2 and Albuminuria, run by Assiut University.
Trial summary
This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity and Diabetes Mellitus, Type 2, Albuminuria
- How many people
- 349 participants
- Where
- No sites listed yet
- Study dates
- 10 Nov 2026to 1 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients aged 18 years or older with established type 2 diabetes mellitus attending Assiut University Hospitals.
Who may be able to join
- - Age 18 years or older
- Established diagnosis of type 2 diabetes mellitus
- Ability to provide written informed consent
Who cannot join
- - Type 1 diabetes mellitus
- Pregnancy
- Acute kidney injury
- Known primary glomerular disease
- Active urinary tract infection
- Decompensated liver disease or active malignancy
- Advanced chronic kidney disease (eGFR <60 mL/min/1.73m²)
- Conditions preventing reliable anthropometric assessment
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Obesity-Related Indices in Association With Albuminuria Level in Patients With Type 2 Diabetes Mellitus
This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus.
Read the detailed description
Type 2 diabetes mellitus is a leading cause of chronic kidney disease. Obesity-related indices such as body mass index, waist-to-height ratio, body roundness index, visceral adiposity index, and triglyceride-glucose index are simple measures of body composition and metabolic status.
This observational study will calculate multiple obesity-related indices and measure urine albumin-to-creatinine ratio in adult patients with type 2 diabetes mellitus.
- Conditions
- Obesity and Diabetes Mellitus, Type 2, Albuminuria
- Keywords
- Type 2 diabetes, Obesity indices, Albuminuria, Body mass index, Assiut
- Medical subject headings
- Obesity, Diabetes Mellitus, Albuminuria, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Type 2 Diabetes Mellitus | Adult patients with established type 2 diabetes mellitus who will undergo anthropometric measurements and laboratory assessment of albuminuria. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Urine albumin-to-creatinine ratio
Mean urine albumin-to-creatinine ratio in milligrams per gram.
Measured: Baseline
Secondary outcomes (4)
Body mass index
Mean body mass index calculated as weight in kilograms divided by height in meters squared.
Measured: Baseline
Waist-to-height ratio
Mean waist-to-height ratio calculated as waist circumference divided by height.
Measured: Baseline
Body roundness index
Mean body roundness index calculated from waist circumference and height.
Measured: Baseline
Estimated glomerular filtration rate
Mean estimated glomerular filtration rate calculated by the CKD-EPI 2021 equation in milliliters per minute per 1.73 square meters.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2026
- Study start10 Nov 2026 (estimated)
- Primary completion10 Nov 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity and Diabetes Mellitus, Type 2Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 349 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mahmoud Marouf Sadek, Assiut University
- Investigators
- Manal E EzzEl-dine Abdel-Mooty, prof, Study chair, Internal Medicine Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07922694
- Sponsor's protocol ID
- Obesity-Indices-T2DM-Assiut
- Status last verified
- Nov 2026
- First submitted
- 2 Nov 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Obesity-Related Indices in Association With Albuminuria Level in Patients With Type 2 Diabetes Mellitus
- ClinicalTrials.gov ID
- NCT07922694
- Acronym / sponsor ID
- Obesity-Indices-T2DM-Assiut
- Conditions
- Obesity and Diabetes Mellitus, Type 2, Albuminuria
- Keywords
- Type 2 diabetes, Obesity indices, Albuminuria, Body mass index, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 349 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 10 Nov 2026 (estimated)
- Primary completion
- 10 Nov 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 6 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to evaluate obesity-related indices and albuminuria levels in patients with type 2 diabetes mellitus.
Detailed description
Type 2 diabetes mellitus is a leading cause of chronic kidney disease. Obesity-related indices such as body mass index, waist-to-height ratio, body roundness index, visceral adiposity index, and triglyceride-glucose index are simple measures of body composition and metabolic status.
This observational study will calculate multiple obesity-related indices and measure urine albumin-to-creatinine ratio in adult patients with type 2 diabetes mellitus.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Type 2 Diabetes Mellitus | – | –Adult patients with established type 2 diabetes mellitus who will undergo anthropometric measurements and laboratory assessment of albuminuria. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients aged 18 years or older with established type 2 diabetes mellitus attending Assiut University Hospitals.
Key inclusion criteria (3 listed)
- - Age 18 years or older
- Established diagnosis of type 2 diabetes mellitus
- Ability to provide written informed consent
Key exclusion criteria (8 listed)
- - Type 1 diabetes mellitus
- Pregnancy
- Acute kidney injury
- Known primary glomerular disease
- Active urinary tract infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Urine albumin-to-creatinine ratio
Time frame: Baseline
Mean urine albumin-to-creatinine ratio in milligrams per gram.
4 secondary outcomes
Body mass index
Time frame: Baseline
Waist-to-height ratio
Time frame: Baseline
Body roundness index
Time frame: Baseline
Estimated glomerular filtration rate
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity and Diabetes Mellitus, Type 2
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Active, not recruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes Mellitus, Overweight
Not yet recruiting
Use and Acceptability of an AI-Assisted Health Application for Individuals Living With a Chronic Condition
Hypertension, Diabetes Mellitus, Type 2
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Manal E EzzEl-dine Abdel-Mooty, prof study chair
Internal Medicine Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Obesity and Diabetes Mellitus, Type 2 and Albuminuria, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mahmoud M Sadek, Resident (01550428880, Mahmud.18313212@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Urine albumin-to-creatinine ratio (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.